ArticleExpert review of clinical pharmacology2009
Acid peptic diseases: pharmacological approach to treatment.
Article in Expert review of clinical pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 128 citations in OpenAlex.
- Pharmacological interventions for prevention and treatment of upper gastrointestinal bleeding in newborn infants.The Cochrane database of systematic reviews · 2019Pooled it
- Safety, Tolerability and Pharmacokinetics of Single Ascending and Multiple Oral Doses of Tegoprazan in Healthy Chinese Subjects.Clinical drug investigation · 2021Trial
- Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children.Journal of gastroenterology · 2018Trial
- Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects.Alimentary pharmacology & therapeutics · 2015Trial
- Efficacy and acceptability of pomegranate effervescent granules in patients suffering from acid peptic disorders.Indian journal of pharmacologyTrial
- Drug Utilization Pattern of Proton Pump Inhibitors in Patients with Acid Peptic Disease and Comorbidities in India: A Real-World Electronic Medical Records-Based Study.Drugs - real world outcomes · 2026Article
- Vonoprazan-based bismuth quadruple therapy for first-line Helicobacter pylori eradication: A real-world, retrospective study.Medicine · 2026Article
- Review
- A Cross-Sectional Study on Gastric Diseases and FGIDs in Bangladesh: Insights Into Causes, Symptoms, and Medications.Health science reports · 2025Article
- Characterization of intestine-specific TRPM6 knockout C57BL/6 J mice: effects of short-term omeprazole treatment.Pflugers Archiv : European journal of physiology · 2025Article
- Population pharmacokinetic analysis of zastaprazan (JP-1366), a novel potassium-competitive acid blocker, in patients and healthy volunteers.CPT: pharmacometrics & systems pharmacology · 2024Article
- Efficacy and Safety of Long-Term Administration of Esomeprazole in Japanese Pediatric Patients Aged 1-14 Years with Chronic Gastric Acid-Related Disease.Pediatric gastroenterology, hepatology & nutrition · 2024Article
- Implementing pharmacogenetic testing to optimize proton-pump inhibitors use among Indian population based on CPIC-CYP2C19-PPI dosing guidelines: The need of the hour.Indian journal of pharmacology · 2024Review
- Proton Pump Inhibitors and Cognitive Health: Review on Unraveling the Dementia Connection and Co-morbid Risks.Current Alzheimer research · 2024Review
- GERD: Latest update on acid-suppressant drugs.Current research in pharmacology and drug discovery · 2024Article
- Acid Peptic Disease among Patients with Acute Abdomen Visiting the Department of Emergency Medicine in a Tertiary Care Centre.JNMA; journal of the Nepal Medical Association · 2023Article
- A real-world retrospective study of omeprazole-domperidone combination in managing acid peptic disease with PRoton-pump Inhibitors in patients with type 2 DiabEtes mellitus (PRIDE-2).Drugs in context · 2023Article
- Gastroprotective Activities of Aqueous and 80% Methanol Leaf Extracts ofJournal of experimental pharmacology · 2023Article
- Therapeutic eradication choices inTherapeutic advances in gastroenterology · 2023Review
- Potassium-competitive acid blockers, a new therapeutic class, and their role in acid-related diseases: a narrative review.Przeglad gastroenterologiczny · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Acid peptic disorders are the result of distinctive, but overlapping pathogenic mechanisms leading to either excessive acid secretion or diminished mucosal defense. They are common entities present in daily clinical practice that, owing to their chronicity, represent a significant cost to healthcare. Key elements in the success of controlling these entities have been the development of potent and safe drugs based on physiological targets. The histamine-2 receptor antagonists revolutionized the treatment of acid peptic disorders owing to their safety and efficacy profile. The proton-pump inhibitors (PPIs) represent a further therapeutic advance due to more potent inhibition of acid secretion. Ample data from clinical trials and observational experience have confirmed the utility of these agents in the treatment of acid peptic diseases, with differential efficacy and safety characteristics between and within drug classes. Paradigms in their speed and duration of action have underscored the need for new chemical entities that, from a single dose, would provide reliable duration of acid control, particularly at night. Moreover, PPIs reduce, but do not eliminate, the risk of ulcers in patients taking NSAIDs, reflecting untargeted physiopathologic pathways and a breach in the ability to sustain an intragastric pH of more than 4. This review provides an assessment of the current understanding of the physiology of acid production, a discussion of medications targeting gastric acid production and a review of efficacy in specific acid peptic diseases, as well as current challenges and future directions in the treatment of acid-mediated diseases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.